Impact of Amrubicin Monotherapy as Second-Line Chemotherapy on Outcomes in Elderly Patients with Relapsed Extensive-Disease Small-Cell Lung Cancer.
Satoshi IgawaTaihei OnoMasashi KasajimaHideaki ManabeTomoya FukuiHisashi MitsufujiMasanori YokobaMasaru KubotaMasato KatagiriJiichiro SasakiKatsuhiko NaokiPublished in: Cancer management and research (2020)
AMR is an effective and feasible regimen for elderly patients with relapsed SCLC after CE therapy.
Keyphrases
- small cell lung cancer
- acute lymphoblastic leukemia
- acute myeloid leukemia
- multiple myeloma
- hodgkin lymphoma
- diffuse large b cell lymphoma
- middle aged
- community dwelling
- combination therapy
- open label
- clinical trial
- brain metastases
- stem cells
- type diabetes
- metabolic syndrome
- squamous cell carcinoma
- randomized controlled trial
- adipose tissue
- cell therapy
- smoking cessation